# CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes

> Randomized placebo-controlled studyAssessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular…

- **Source:** [Prnewswire](https://www.prnewswire.com/news-releases/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-302809846.html?utm_source=gearopen.com&utm_medium=referral&utm_campaign=feed&utm_content=6a3cd51eb2b3e3a865b48e92)
- **Published:** 2026-06-25
- **Category:** Science
- **Tags:** #breakthrough #diabetes #dosing #insulin #phase #type #begins #supported
- **Canonical:** http://localhost:4321/a/6a3cd51eb2b3e3a865b48e92

---

_GearOpen's distilled summary. The full original article is published at Prnewswire (source link above); GearOpen does not republish the source's full text._